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Abstract 
Exercise stress echocardiograms (ESE) are a functional cardiovascular (CV) test typically 
used for the investigation of coronary artery disease (CAD). ESEs are often terminated at a 
pre-determined age-predicted maximum heart rate (APMHR) to facilitate timely acquisition 
of ultrasound images at peak exercise. While an APMHR of 85% is often used, this has not 
been validated as a suitable termination endpoint. Heart rate blood pressure product (HRBPP) 
as an established measure of myocardial work may provide a more reliable assessment of 
cardiac workload. The aim of this study was to assess maximal HRBPP (MHRBPP) and 
APMHR as markers of cardiac workload during ESE, using CV events at mean follow-up as 
the outcome variable. Following exclusions, 712 patients being investigated for ischemic 
heart disease, performed an ESE to volitional fatigue using the standard Bruce protocol. 
Patient demographics and test data were collected and patients followed for 4.4 ± 2.1 years.  
Cut-points for MHRBPP (25060) (AUC 0.77) and PMHR (93.8% and 97.9%) (AUC 0.71) 
(p=0.12 for difference) were established from receiver operating characteristic analysis.  
Those achieving an APMHR >85% but MHRBPP <25060 had significantly more CV events 
then achieving an MHRBPP >25060 regardless of APMHR (p<0.05). In conclusion, the 
current study demonstrates the superior prognostic power of MHRBPP over APMHR alone 
for the prediction of future CV events in patients performing an otherwise negative ESE for 
the detection of myocardial ischemia. 
 
 
Key Words: Rate Pressure Product, Exercise Stress Echocardiogram, Myocardial Ischemia, 
Double Product. 
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Generally, the diagnostic accuracy of the exercise stress echocardiogram (ESE) is 
superior to the exercise stress test (EST) however this often depends on the patient population 
being studied, the image quality and test interpreter skill level (1- 5). The added advantage of 
ESE is the acquisition of ultrasound images to detect regional wall motion abnormalities 
(RWMA) linked to myocardial ischemia, particularly when the resting electrocardiogram 
(ECG) is uninterpretable (5). ESEs are often terminated at an age-predicted maximum heart 
rate (APMHR) of 85% to allow the patient to move quickly into a supine position for peak 
image acquisition as RWMA may resolve quickly (1, 6, 7). Heart rate blood pressure product 
(HRBPP), as an established estimate of myocardial oxygen consumption and, therefore, 
myocardial work (8, 9), is often recorded during an ESE but not commonly used as a marker 
of sufficient cardiac workload (1). Maximum HRBPP (MHRBPP) has been shown to be a 
predictor of cardiovascular (CV) outcome during ESTs, displaying superiority over APMHR 
to predict CV events (10).  Therefore, MHRBPP may provide a more reliable assessment of 
cardiac workload than APMHR for the prediction of CV events during ESEs.  The aim of this 
study was to compare MHRBPP and APMHR as predictors of future CV events in 
intermediate risk patients performing an otherwise negative ESE. 
Methods 
The study sample was retrieved from the Logan Hospital, a public hospital in 
southeast Queensland, Australia, and was approved by the Metro South Health Service 
District Human Research Ethics Committee, conforming to the declaration of Helsinki. 
Retrospective data from consecutive ESEs performed between 01/01/2010 and 31/12/2014 
for the investigation of inducible myocardial ischemia were included (n=783). Any test 
considered positive by RWMA, ECG criteria, symptoms, or patients with > mild resting left 
ventricular (LV) dysfunction (n=71) were excluded, as downstream management strategies 
would differ in this group. The total number of tests remaining for analysis was 712. 
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Echocardiography images were obtained with a Philips IE33 ultrasound machine (Philips 
Medical Systems, Andover, MA) in the left lateral decubitus position. Image analysis was 
performed as per American Society of Echocardiography guidelines (7). The treadmill 
exercise was administered on a computer-controlled treadmill system (Marquette Case, 
Milwaukee, WI), performed to volitional fatigue, using the standard Bruce protocol (11). 
Manual blood pressure measurements were taken by an experienced operator at least once 
every stage, at peak exercise, and a minimum of twice during recovery. HRBPP was 
calculated by multiplying heart rate by systolic blood pressure (SBP) throughout the test and 
MHRBPP was identified. Mean follow up was 4.4 ± 2.1 years by reference to medical 
records, inclusive of mortality registry or contact with the patients’ general practitioners. 
Quantitative data were summarised as mean ± standard deviation and the student t-test 
or Fisher’s exact test were used where appropriate. To establish a cut-point for MHRBPP and 
APMHR, receiver operating characteristic (ROC) analysis was used to calculate sensitivity 
and specificity with respect to CV events (CV mortality, non-fatal myocardial infarction, 
stroke or heart failure (minimum stage C) (12), percutaneous coronary intervention (PCI) / 
balloon angioplasty or coronary artery bypass grafting) at mean follow-up as the outcome 
measure.  The longest vertical deviation from the diagonal line was chosen as the optimal cut-
point. Kaplan-Meier survival analysis was used to evaluate CV events, CV mortality and all-
cause mortality for those above and below the optimal cut points. The log-rank test was used 
to assess statistical significance. Cox proportional hazard models were created to assess 
variables significant for CV events. Variables were selected from baseline differences 
between those with and without CV events (Table 1 and 2). Likewise, inability to achieve the 
ROC cut-points were included in the model with entry and multivariate retention set at 0.05 
significance. Multivariate analysis was performed to assess factors influencing the ability to 
achieve the ROC cut-points including age, smoking status, heart rate and blood pressure 
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medications. Categorical data were compared using the chi-square or Fisher’s exact test, 
where appropriate. Data analysis was performed using XLSTAT 2018.7 (Addinsoft, New 
York) with a 2-tailed p-value <0.05 considered statistically significant. 
Results 
Table 1 displays the physical attributes of the patients together with their ESE 
measures for those with and without CV events during follow-up.  Table 2 lists the CV 
disease risk factors and medications of the patients at time of testing. Those with CV events 
were older, performed less exercise with less myocardial work during their test and had more 
resting abnormalities on their echocardiograms (Table 1). They also exhibited more CAD, 
used more medications and overall displayed a greater CV disease risk (Table 2).   
ROC analyses revealed an optimal cut-point of 25060 for MHRBPP (sensitivity 76%, 
specificity 78.2%, [area under curve (AUC) 0.77]. For APMHR, the optimal cut-point was 
equal between 2 points; 93.8% (sensitivity 63.8%, specificity 69.4%) and 97.9% (sensitivity 
79.3%, specificity 53.9%) (AUC 0.71). At 85% APMHR, the sensitivity and specificity were 
27.6% and 91.8% respectively. The difference between the two models failed to reach 
statistical significance (p = 0.12) (Figure 1).  
There was no CV mortality throughout the follow-up period. Figure 2 illustrates the 
Kaplan-Meier curves for all-cause mortality and CV events with respect to the MHRBPP cut 
point of 25060 and APMHR of 85%. There was no significant difference in all-cause 
mortality for all interactions of MHRBPP > or ≤25060 and APMHR > or ≤85% (Figure 2a).  
In contrast, the cumulation of CV events was significantly less in those achieving >25060 
MHRBPP or >85% APMHR compared to MHRBPP ≤25060 and APMHR ≤85% (p<0.05) 
(Figure 2b). From 3 years follow-up, those attaining a MHRBPP >25060 had significantly 
less events than those reaching >85% APMHR (p<0.05) (Figure 2b).  
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Table 3 shows the outcome of Cox proportional hazard analysis for predicting CV 
events. After adjustments, only age, the presence of diabetes, previous CAD and an 
MHRBPP <25000 remained as significant predictors.  
No CV medication influenced the ability to achieve the cut-points for APMHR and 
MHRBPP. For all cut-point levels of APMHR (<85%, <94%, <98%) only a younger age was 
a significant factor for the inability to achieve above these levels (p<0.05). There was no 
significant factor influencing MHRBPP other than the components maximum heart rate and 
maximum SBP (p<0.05).  
Discussion 
The current study demonstrates MHRBPP as a reasonable prognostic measure of 
future CV events (AUC = 0.77). While the overall diagnostic model between MHRBPP and 
APMHR failed to reach significance (p=0.12) (Figure 1), no level of APMHR predicted 
future CV events (Table 3). In comparison, inability to achieve the ROC cut-point for 
MHRBPP >25060 was a strong uni and multivariate predictor of CV events (Table 3).  An 
APMHR of 85% is often used as a marker of sufficient stress during treadmill exercise (13). 
Our study found this value exhibited poor sensitivity (27.6%) for the detection of future CV 
events in otherwise negative studies (Figure 1). The use of 85% APMHR comes from studies 
demonstrating that failure to achieve this level is a marker of chronotropic incompetence (14, 
15). No study has shown this level of APMHR as a sufficient marker of cardiac workload 
during exercise yet many still use this as a termination point during exercise testing despite 
guideline recommendations (2, 16, 17). The current study shows even achieving an APMHR 
>85% did not predict a better outcome compared to an MHRBPP >25060 (Figure 2b). 
There was a significant difference for CV event frequency during follow-up between 
those achieving an MHRBPP >25060 and those below (Figure 2b). Previous work by 
Whitman et al. demonstrated similar results in those with poor functional capacity but 
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MHRBPP >25000 during an EST (10). In the current study, resting LV dysfunction was 
found to be an independent predictor of future CV events (Table 3). Elhendy et al. 
demonstrated similar results with resting echocardiogram abnormalities and poorer CV 
outcomes in those unable to achieve 85% APMHR and, although not discussed, an inability 
to reach an HRBPP of 25000 during an ESE (15). Advancing age, diabetes, hypertension and 
the presence of CAD have all been shown to increase CV disease risk (18, 19). This is 
confirmed in the current study as these risk factors were all significantly different between 
the CV event group and the no CV event group (p<0.05) (Table 2). The greatest predictor for 
CV events in the current study was failure to reach an MHRBPP of >25060 (Table 3). In a 
study by Sadrzadeh Rafie at el. (20), HRBPP reserve (the difference between rest and 
maximal exercise) was a stronger predictor of CV outcome than even exercise capacity, a 
known CV prognostic marker (21). Similarly, we found the inability to achieve an MHRBPP 
>25060 to be a strong CV event predictor with exercise capacity failing to predict CV events 
in the current study (Table 3). The ability to increase SBP alone during an ESE has been 
associated with a significantly lower risk of future CV events (22). Therefore, it appears the 
blood pressure response during exercise is equally as important as the heart rate response and 
should be used in conjunction (i.e. MHRBPP) to maximise the prognostic power for the 
prediction of CV events.  
There are some limitations to this study. Firstly, our study is a single centre cohort 
and therefore the decision to perform an ESE may have been subject to selection bias. 
Secondly, while most of our patients were risk stratified as intermediate/moderate risk for CV 
disease, the total event rate during follow-up was only 8% suggesting a lower overall risk. 
Finally, like all predictive models, care should be taken not to replace clinical suspicion in 
patients deemed to be at sufficient future CV event risk.  
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In conclusion, the current study demonstrates the superior prognostic power of 
MHRBPP over APMHR alone for the prediction of future CV events in patients performing 
an otherwise negative ESE to volitional fatigue. While APMHR has been used as a marker of 
sufficient myocardial work in the past, the current study demonstrates the value of MHRBPP 
during exercise testing and warrants further investigation in this area. 
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Figure 1. Receiver operating characteristic curve for maximum heart rate blood pressure 
product (MHRBPP) and age-predicted maximal heart rate (APMHR). The bold arrow 
indicates the optimal cut-point for MHRBPP. The dotted arrow (93.8%) and dashed arrow 
(97.9%) indicate the optimal cut-points for APMHR. The black dot specifies the data point at 
85% APMHR. 
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Figure 2. Kaplan Meier curve for a. all-cause mortality and b. cardiovascular events for 
maximum heart rate blood pressure product > and ≤ 25060 and age-predicted maximum heart 
rate > and ≤85% 
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Variable 
CV Events (n=58) 
No CV Events 
(n=657) 
p-Value 
Age (years) 60.0 ± 10.4 #  52.8 ± 11.5  <0.01 
Men 36 (62.1%) 316 (48.1%) 0.25 
Resting heart rate (bpm) 75 ± 14  79 ± 14 # 0.02 
Resting systolic blood pressure (mmHg) 132 ± 19 128 ± 18 0.18 
Resting heart rate blood pressure product 9820 ± 2311 10212 ± 2435 0.24 
Maximum heart rate (bpm) 143 ± 18* 164 ± 19*# <0.01 
Maximum systolic blood pressure (mmHg) 166 ± 27* 171 ± 21* 0.08 
Maximum heart rate blood pressure product 23762 ± 4839* 28045 ± 4731*# <0.01 
Test Duration (min:sec) 7:17 ± 2:48  8:42 ± 2:33 #  <0.01 
Metabolic equivalents 8.8 ± 3.0 10.4 ± 2.8 # <0.01 
Resting regional wall motion abnormalities  9 (15.5%) # 25 (3.8%) <0.01 
Diastolic dysfunction 14 (24.1%) 89 (13.6%) 0.09 
Mildly impaired resting ejection fraction  4 (6.9%) # 10 (1.5%) 0.02 
 
Table 1. Physical characteristics and ESE measures for those with and without cardiovascular (CV) 
events during follow-up. Values show number of cases (n), mean ± SD or percentage (%) of the 
group. * significant from resting values p<0.05.  
# significant between CV event and no CV event group p<0.05. 
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Variable 
CV Events 
(n=58) 
No CV Events 
(n=657) 
p-Value 
CV disease risk factors 3.1 ± 1.3  2.1 ± 1.3 <0.01 
No risk factors for CV disease 3 (5.2%) 78 (11.9%) 0.19 
Family history of CV disease 17 (29.3%)  204 (31.1%) >0.99 
Diabetes Mellitus  19 (32.8%) 112 (17.0%) 0.03 
Smoker 14 (24.1%) 156 (23.7%) >0.99 
Hypertension  39 (67.2%) 282 (42.9%) 0.04 
Dyslipidemia  45 (77.6%) 322 (49.0%) 0.04 
Obesity  17 (29.3%) 220 (33.5%) 0.78 
Prior coronary artery disease 31 (53.4%) 91 (13.9%) <0.01 
Medications per patient 3.3 ± 1.9 1.7 ± 1.7 <0.01 
No medications  6 (10.3%) 232 (35.3%) <0.01 
β blockers  31 (53.4%) 148 (22.5%) <0.01 
Ca2+ blockers  13 (22.4%) 71 (10.8%) 0.04 
Angiotensin converting enzyme inhibitors  22 (37.9%) 139 (21.1%) 0.03 
Angiotensin receptor blockers 13 (22.4%) 115 (17.5%) 0.49 
Nitrates  9 (15.5%) 15 (2.3%) <0.01 
Statins  35 (60.3%) 269 (40.9%) 0.10 
Diuretics 7 (12.1%) 44 (6.7%) 0.19 
Aspirin  36 (62.1%) 244 (37.1%) 0.03 
Non-vitamin K antagonist 2 (3.4%) 3 (0.5%) 0.06 
P2y12 inhibitor  16 (27.6%) 53 (8.1%) <0.01 
Warfarin  4 (6.9%) 10 (1.5%) 0.02 
 
Table 2. Cardiovascular (CV) disease risk factors and medications at time of stress test for those with 
and without CV events during follow-up . Values show number of cases (n), ± SD or percentage (%) of 
the group.  
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Variable 
Univariate 
Hazard Ratio 
(95% CI) 
Chi 
Square 
p-Value 
Multivariate  
Hazard Ratio  
(95% CI) 
Chi 
Square 
p-Value 
       
Age 1.06 (1.02-1.10) 9.1 0.003 1.06 (1.03-1.09) 16.8 <0.0001 
Men 1.14 (0.54-2.40) 0.2 0.738 - - - 
Diabetes Mellitus 2.57 (1.28-5.17) 7.0 0.008 2.77 (1.48-5.17) 10.2 0.001 
Hypertension 2.58 (1.09-6.11) 4.7 0.031 2.02 (0.91-4.48) 2.9 0.086 
Dyslipidemia 0.94 (0.44-2.00) 0.1 0.872 - - - 
Prior coronary artery disease 3.20 (1.51-6.80) 9.2 0.002 2.56 (1.43-4.57) 10.0 0.002 
β-Blocker use 1.22 (0.63-2.37) 0.4 0.551 - - - 
Calcium channel blocker use 0.63 (0.28-1.42) 1.2 0.265 - - - 
Angiotensin converting 
enzyme inhibitor use 
1.36 (0.70-2.66) 0.8 0.365 - - - 
Nitrate use 2.72 (1.05-7.05) 4.2 0.040 2.17 (0.99-4.75) 3.7 0.052 
Aspirin use 0.66 (0.34-1.27) 1.6 0.213 - - - 
P2Y12 inhibitor use 0.51 (0.23-1.13) 2.7 0.099 - - - 
Warfarin 0.33 (0.08-1.41) 2.3 0.133 - - - 
<7:17min:sec treadmill time 3.64 (0.45-29.8) 1.5 0.228 - - - 
<8.8 metabolic equivalents 0.19 (0.02-1.56) 2.4 0.122 - - - 
<85% Age predicted 
maximum heart rate 
1.53 (0.67-3.48) 1.1 0.311 - - - 
<94% Age predicted 
maximum heart rate 
0.63 (0.25-1.55) 1.1 0.312 - - - 
<98% Age predicted 
maximum heart rate 
1.83 (0.68-4.92) 1.4 0.232 - - - 
Resting regional wall  
motion abnormalities 
0.30 (0.00-0.91) 4.6 0.033 0.43 (0.15-1.20) 2.6 0.105 
Maximum heart rate blood 
pressure product <25060 
7.64 (3.40-17.2) 24.2 <0.0001 6.21 (3.26-11.8) 30.9 <0.0001 
Mildly impaired resting left 
ventricular ejection fraction 
6.03 (1.30-27.9) 5.3 0.022 3.59 (0.94-13.8) 3.5 0.063 
 
Table 3. Univariate and multivariate predictors of cardiovascular events from exercise stress 
echocardiogram results.  
 
